Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Climb Bio (Nasdaq: CLYM) has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference. The company's executive team will be presenting at this virtual event, which is scheduled to take place from April 7-10, 2025.

The presentation is specifically scheduled for April 10, 2025, at 8:45 a.m. ET. The format will include both a formal presentation and one-on-one investor meetings, providing opportunities for direct engagement with the company's leadership.

News Market Reaction 1 Alert

-2.31% News Effect

On the day this news was published, CLYM declined 2.31%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

03/27/2025 - 07:00 AM

WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24^th Annual Needham Healthcare Conference being held virtually April 7-10, 2025.

24^th Annual Needham Virtual Healthcare Conference
Format: Presentation and one-on-one investor meetings
Date: April 10, 2025
Time: 8:45 a.m. ET
Webcast: Click here

About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody currently in IND-enabling studies for IgA nephropathy. For more information, please visit climbbio.com.

Investors
Chris Brinzey
ICR Healthcare
chris.brinzey@icrhealthcare.com
339-970-2843

Media
Jon Yu
ICR Healthcare
jon.yu@icrhealthcare.com
475-395-5375